 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Evaluation of guanidinium-based medium for GeneXpert and SmartGene to detection of SARS-CoV-2 RNA |
| Language |
J |
| AuthorList |
Yuzuka Kawamoto1), Daisuke Sakanashi1), Mina Takayama1), Narimi Miyazaki1), Tomoko Ohno1), Atsuko Yamada1), Akiko Nakamura1), Hirotoshi Ohta1), Hiroyuki Suematsu1), Sumie Chida2), Jun Hirai1,2), Yuka Yamagishi2,3), Hiroshige Mikamo1,2) |
| Affiliation |
1) Department of Infection Control and Prevention, Aichi Medical University Hospital
2) Department of Clinical Infectious Diseases, Aichi Medical University Hospital
3) Department of Clinical Infectious Diseases, Kochi Medical School University |
| Publication |
J.J.C.M.: 33 (3), 201-205, 2023 |
| Received |
December 23, 2022 |
| Accepted |
March 16, 2023 |
| Abstract |
The COVID-19 is diagnosed by reverse-transcription PCR in clinical laboratories. A medium containing guanidium thiocyanate is able to inactivate SARS-CoV-2 at the time of specimen collection, and it may reduce the risk of infection. In this study, we aimed to verify the suitability of guanidinium-based medium (GBM) for GeneXpert and SmartGene to detect SARS-CoV-2 RNA. The clinical specimens of nasopharyngeal swabs were collected from patients using a universal transport medium (UTM) or a GBM. The specimens were diagnosed by the reference method; cobas 8800. Thirty positive and fifteen negative specimens were selected from both group of UTM and GBM, and re-assayed in GeneXpert and SmartGene. As the result, no PCR inhibition result was observed for any specimen. The positive/negative agreement rates (%) of the combination settings using reference were as follows: GeneXpert-UTM 93/100; GeneXpert-GBM 100/100; SmartGene-UTM 80/100; and SmartGene-GBM 77/100. For the difference of the threshold cycle values with reference method, GBM-group was significantly lower (p < 0.01) than UTM-group, in both GeneXpert and SmartGene. In summary, our result suggested that the GBM can be an alternative tool to perform GeneXpert and SmartGene for the detection of SARS-CoV-2 RNA. We believe that GBM would provide a safety work-flow in the clinical laboratory. |
| Keywords |
GeneXpert, SmartGene |
|
